I think that is very possible with growing sales of Daybue lifting us up into higher royalty rates and generating significantly more royalty revenue for us plus one or 2 more milestone payments to underpin our financial credentials. And add to that, positive results of Ph II trials of 2591 for Pitt Hopkins in Q2 '24 and for Angelman in Q3 '24. Add to that the progression of the design of Ph III trials of 2591 for Phelan McDermid with the FDA by the end of Q4 '24 to begin in '25 with highly anticipated positive results. And who knows when Acadia might announce some progress of Trofinetide trials for Fragile X. There's a huge amount still to come just in the next 12 months, and then in the next 12 months after that.
Take Over Opportunity, page-5
-
- There are more pages in this discussion • 44 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.05 |
Change
-0.510(3.50%) |
Mkt cap ! $1.795B | |||
| Open | High | Low | Value | Volume |
| $14.38 | $14.42 | $13.94 | $6.419M | 454.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $13.99 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.07 | 6644 | 4 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| NEU (ASX) Chart |